Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telomir Pharmaceuticals, Inc. ( (TELO) ) has provided an update.
On May 29, 2025, Telomir Pharmaceuticals announced promising preclinical results for Telomir-1, a treatment for AMD, using a zebrafish model. The study showed that Telomir-1 improved vision, restored retinal structure, reduced oxidative stress, and enhanced survival rates, marking a significant milestone towards its advancement to clinical trials.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of innovative treatments for age-related diseases. The company is currently developing Telomir-1, an oral small molecule candidate aimed at treating age-related macular degeneration (AMD).
Average Trading Volume: 168,314
Technical Sentiment Signal: Sell
Current Market Cap: $62.5M
See more insights into TELO stock on TipRanks’ Stock Analysis page.